Nephrology Service, Hospital General de México 'Dr Eduardo Liceaga', Mexico.
Research Department, Hospital General de México 'Dr Eduardo Liceaga', Mexico.
Biomark Med. 2022 Oct;16(14):1019-1028. doi: 10.2217/bmm-2022-0364. Epub 2022 Sep 2.
The enzyme lactate dehydrogenase (LDH) is a good marker of general hyperinflammation correlated with mortality for COVID-19, and is therefore used in prognosis tools. In a current COVID-19 clinical randomized trial (CRT), the blood level of LDH was selected as an inclusion criterion. However, LDH decreased during the pandemic; hence, the impact of this decrease on the prognostic value of LDH for mortality was evaluated. Data on LDH levels in 843 patients were obtained and analyzed. Relative risk, standard error and receiver operating characteristic curves were calculated for two cutoff values. Relative risk lost validity and the area under the curve narrowed by trimester during the pandemic. The progressive decrease in LDH impacted the capacity to predict mortality in COVID-19. More studies are needed to validate this finding and its implications.
乳酸脱氢酶（LDH）是一种与 COVID-19 死亡率相关的全身性高炎症的良好标志物，因此被用于预后工具。在当前的 COVID-19 临床随机试验（CRT）中，LDH 水平被选为纳入标准。然而，在大流行期间 LDH 水平降低；因此，评估了这种降低对 LDH 死亡率预后价值的影响。获取并分析了 843 名患者的 LDH 水平数据。计算了两个截止值的相对风险、标准误差和接收者操作特征曲线。相对风险在大流行期间失去了有效性，曲线下面积随着时间的推移而缩小。LDH 的逐渐降低影响了 COVID-19 患者预测死亡率的能力。需要更多的研究来验证这一发现及其意义。
